Emerging Immunotherapy Approaches for Treating Prostate Cancer

被引:20
作者
Meng, Lingbin [1 ]
Yang, Yuanquan [1 ]
Mortazavi, Amir [1 ]
Zhang, Jingsong [2 ]
机构
[1] Ohio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA
[2] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Genitourinary Oncol, 12902 USF Magnolia Dr, Tampa, FL 33612 USA
关键词
immunotherapy; prostate cancer; immune checkpoint inhibitors; bispecific antibodies; CAR T cells; vaccines; cytokines; immunotherapeutic combinations; CAR-T-CELLS; IMMUNE-CHECKPOINT; DOUBLE-BLIND; PHASE-III; PLUS DOCETAXEL; CLINICAL-TRIAL; SIPULEUCEL-T; TUMOR MICROENVIRONMENT; DNA VACCINE; ANTIGEN;
D O I
10.3390/ijms241814347
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immunotherapy has emerged as an important approach for cancer treatment, but its clinical efficacy has been limited in prostate cancer compared to other malignancies. This review summarizes key immunotherapy strategies under evaluation for prostate cancer, including immune checkpoint inhibitors, bispecific T cell-engaging antibodies, chimeric antigen receptor (CAR) T cells, therapeutic vaccines, and cytokines. For each modality, the rationale stemming from preclinical studies is discussed along with outcomes from completed clinical trials and strategies to improve clinical efficacy that are being tested in ongoing clinical trials. Imperative endeavors include biomarker discovery for patient selection, deciphering resistance mechanisms, refining cellular therapies such as CAR T cells, and early-stage intervention were reviewed. These ongoing efforts instill optimism that immunotherapy may eventually deliver significant clinical benefits and expand treatment options for patients with advanced prostate cancer.
引用
收藏
页数:26
相关论文
共 186 条
[1]   Genomic correlates of clinical outcome in advanced prostate cancer [J].
Abida, Wassim ;
Cyrta, Joanna ;
Heller, Glenn ;
Prandi, Davide ;
Armenia, Joshua ;
Coleman, Ilsa ;
Cieslik, Marcin ;
Benelli, Matteo ;
Robinson, Dan ;
Van Allen, Eliezer M. ;
Sboner, Andrea ;
Fedrizzi, Tarcisio ;
Mosquera, Juan Miguel ;
Robinson, Brian D. ;
De Sarkar, Navonil ;
Kunju, Lakshmi P. ;
Tomlins, Scott ;
Wu, Yi Mi ;
Rodrigues, Daniel Nava ;
Loda, Massimo ;
Gopalan, Anuradha ;
Reuter, Victor E. ;
Pritchard, Colin C. ;
Mateo, Joaquin ;
Bianchini, Diletta ;
Miranda, Susana ;
Carreira, Suzanne ;
Rescigno, Pasquale ;
Filipenko, Julie ;
Vinson, Jacob ;
Montgomery, Robert B. ;
Beltran, Himisha ;
Heath, Elisabeth I. ;
Scher, Howard I. ;
Kantoff, Philip W. ;
Taplin, Mary-Ellen ;
Schultz, Nikolaus ;
deBono, Johann S. ;
Demichelis, Francesca ;
Nelson, Peter S. ;
Rubin, Mark A. ;
Chinnaiyan, Arul M. ;
Sawyers, Charles L. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (23) :11428-11436
[2]   Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy [J].
Abou-el-Enein, Mohamed ;
Elsallab, Magdi ;
Feldman, Steven A. ;
Fesnak, Andrew D. ;
Heslop, Helen E. ;
Marks, Peter ;
Till, Brian G. ;
Bauer, Gerhard ;
Savoldo, Barbara .
BLOOD CANCER DISCOVERY, 2021, 2 (05) :408-422
[3]  
Adkins Sherry, 2019, J Adv Pract Oncol, V10, P833, DOI 10.6004/jadpro.2019.10.8.5
[4]   Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021) [J].
Agarwal, Neeraj ;
McGregor, Bradley ;
Maughan, Benjamin L. ;
Dorff, Tanya B. ;
Kelly, William ;
Fang, Bruno ;
McKay, Rana R. ;
Singh, Parminder ;
Pagliaro, Lance ;
Dreicer, Robert ;
Srinivas, Sandy ;
Loriot, Yohann ;
Vaishampayan, Ulka ;
Goel, Sanjay ;
Curran, Dominic ;
Panneerselvam, Ashok ;
Schwickart, Martin ;
Choueiri, Toni K. ;
Pal, Sumanta .
LANCET ONCOLOGY, 2022, 23 (07) :899-909
[5]   Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC). [J].
Aggarwal, Rahul Raj ;
Rottey, Sylvie ;
Aparicio, Ana ;
Greil, Richard ;
Reimers, Melissa Andrea ;
Sandhu, Shahneen Kaur ;
Zhang, Yiran ;
Salvati, Mark ;
Sadraei, Nooshin Hashemi .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[6]   Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTEimmune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC). [J].
Aggarwal, Rahul Raj ;
Aparicio, Ana ;
Heidenreich, Axel ;
Sandhu, Shahneen Kaur ;
Zhang, Yiran ;
Salvati, Mark ;
Shetty, Aditya ;
Sadraei, Nooshin Hashemi .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[7]   Multiplex bioimaging of single-cell spatial profiles for precision cancer diagnostics and therapeutics [J].
Allam, Mayar ;
Cai, Shuangyi ;
Coskun, Ahmet F. .
NPJ PRECISION ONCOLOGY, 2020, 4 (01)
[8]   LAG3 (CD223) as a cancer immunotherapy target [J].
Andrews, Lawrence P. ;
Marciscano, Ariel E. ;
Drake, Charles G. ;
Vignali, Dario A. A. .
IMMUNOLOGICAL REVIEWS, 2017, 276 (01) :80-96
[9]   Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study [J].
Antonarakis, E. S. ;
Piulats, J. M. ;
Gross-Goupil, M. ;
Goh, J. C. ;
Vaishampayan, U. N. ;
De Wit, R. ;
Alanko, T. V. ;
Fukasawa, S. ;
Tabata, K. ;
Feyerabend, S. ;
Berger, R. ;
Ojamaa, K. ;
Hoimes, C. J. ;
Sezer, A. ;
Omlin, A. G. ;
Yachnin, J. ;
Niu, C. ;
Poehlein, C. H. ;
Schloss, C. ;
de Bono, J. S. .
ANNALS OF ONCOLOGY, 2021, 32 :S651-S652
[10]  
Antonarakis ES, 2023, J CLIN ONCOL, V41, P3839, DOI 10.1200/JCO.23.00233